Molecular Partners Ag MOLN
NASDAQ MOLN
$4.18 -0.17 (-3.76%)
As of: Sep 10, 2026 · 9:51 AM EDT

Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026)

Molecular Partners Ag's (MOLN) quarterly Change in Receivables came in at $1.2 million in Q2 2026, up 179.81% year-over-year from $440879.9 in Q2 2025, and up 297.95% quarter-over-quarter from -$623178.3 in Q1 2026.

Analysis

Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026) Analysis & Trends

Molecular Partners Ag (MOLN) has reported Change in Receivables for 7 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Change in Receivables rose 179.81% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $2.8 million, a 1554.71% increase from a year earlier, with the FY2025 full-year figure at $584972.3, up 248.31% from the prior year.
  • Change in Receivables was $1.2 million for Q2 2026 at Molecular Partners Ag, up from -$623178.3 in the prior quarter.
  • Over five years, Change in Receivables peaked at $24.6 million in Q1 2022 and troughed at -$1.8 million in Q1 2025.
  • A 5-year average of $1.5 million and a median of $302369.0 in 2023 frame the typical range for Change in Receivables.
  • Across the five-year window, Change in Receivables slumped 185.34% in 2024 and jumped 3213.37% in 2025, its largest moves.
  • Over 5 years, Change in Receivables stood at $726615.3 in 2022, then slumped by 131.5% to -$228853.0 in 2023, then soared by 599.3% to $1.1 million in 2024, then tumbled by 70.44% to $337815.8 in 2025, then jumped by 265.17% to $1.2 million in 2026.
  • The last three Change in Receivables figures came in at $1.2 million (Q2 2026), -$623178.3 (Q1 2026), and $337815.8 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 1.09 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 333.00 Mn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 140.20 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 838.50 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -53.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 31.60 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 269.40 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Molecular Partners Ag 156.54 Mn 156.54 Mn - 1.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.23 Mn
Mar 31, 2026 -623,178.28
Dec 31, 2025 337,815.84
Sep 30, 2025 1.87 Mn
Jun 30, 2025 440,879.93
Mar 31, 2025 -1.83 Mn
Dec 31, 2024 1.14 Mn
Sep 30, 2024 56,556.15
Jun 30, 2024 -227,793.46
Mar 31, 2024 -1.36 Mn
Dec 31, 2023 -228,852.96
Sep 30, 2023 -295,491.82
Jun 30, 2023 266,922.13
Mar 31, 2023 -766,544.27
Dec 31, 2022 726,615.34
Sep 30, 2022 1.01 Mn
Jun 30, 2022 869,051.25
Mar 31, 2022 24.64 Mn
Dec 31, 2021 -22.42 Mn
Sep 30, 2021 2.52 Mn